Interferon-mediated anti-angiogenic therapy for neuroblastoma.
Angiogenesis appears to be a fundamental requirement for tumor growth, invasion and metastasis. Evidence also exists to suggest that inhibition of tumor-associated angiogenesis can retard tumor growth and prevent tumor spread. Several naturally occurring angiogenesis inhibitors have been identified, including type I interferons (alpha/beta). These proteins are potent inhibitors of angiogenesis and may also have direct anti-tumor and immunomodulatory effects. Because anti-angiogenic therapy is likely cytostatic, long-term delivery of angiogenesis inhibitors may be required for the successful treatment of cancer. We have, therefore, explored the utility of a gene therapy-mediated approach for the delivery of interferon-beta and tested this approach, both alone and in combination with conventional chemotherapy, in murine models of neuroblastoma.
Streck
Christian J
CJ
Department of Surgery, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
Ng
Catherine Y C
CY
Zhang
Youbin
Y
Zhou
Junfang
J
Nathwani
Amit C
AC
Davidoff
Andrew M
AM
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D015316:Genetic Therapy; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D009447:Neuroblastoma / Q000098:blood supply / Q000188:drug therapy* / Q000628:therapy
D020533:Angiogenesis Inhibitors; D007372:Interferons